Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention
Conditions
Keywords
Flash, FFR, caFFR, coronary angiography-derived fractional flow reserve, Coronary Artery Disease, Myocardial Ischaemia, Percutaneous Coronary Intervention, Coronary Circulation
Brief summary
The overall purpose of Flash FFR Ⅱ is to investigate whether coronary angiography-derived fractional flow reserve (caFFR), compared with fractional flow reserve (FFR) measured by a pressure wire, has non-inferior clinical effect and cost benefit in guiding the percutaneous coronary intervention (PCI) for patients with moderate coronary artery stenosis in terms of long-term clinical prognosis.
Detailed description
Flash FFR Ⅱ is a prospective, multicenter, blinded, randomized, non-inferiority trial. Eligible patients with moderate coronary artery stenosis will be included in the study and randomly assigned to either caFFR-guided group or FFR-guided group. Participant caFFR or FFR will be used to guide percutaneous coronary intervention (PCI) strategy. The rate of major cardiovascular adverse events (MACE) and the cost data will be collected during the long-term follow-up (2 years). MACE is defined as a composite of all-cause death, myocardial infarction (MI), unplanned revascularization. Clinical outcomes and cost-effectiveness will be compared between the two groups. A subgroup analysis is pre-set and included in the protocol, including age, sex, body mass index, diabetes mellitus, smoking status, mean aortic pressure (resting state), acute coronary syndrome, left ventricular ejection fraction, lesion site, lesion stenosis severity, target vessel reference diameter, small vessel lesion, blood flow velocity, PCI mode, and so on. The trial is equipped with a core laboratory. Some interesting sub-studies will be carried out, such as a comparison of laboratory and operator analysis results. If the trial results show non-inferiority, it should be noted that caFFR can bring new benefits to both operators and patients as a new index of physiological assessment of coronary artery stenosis severity with the advantages of lower cost, less risk, faster time, and less use of resources.
Interventions
DIAGNOSTIC_TESTcaFFR
caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off \> 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.
DIAGNOSTIC_TESTFFR
FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
Sponsors
Rainmed Ltd., Suzhou, China
Peking University First Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)
Masking description
In the Flash FFR II study, clinical outcome assessors (including the follow-up research personnel, clinical events committee (CEC), data and safety monitoring board (DSMB), and core laboratory) will be blinded to randomization arm. The data safety monitoring board (DSMB) may request unblinding of grouping information due to patient safety reasons. All the study site personnel will receive training for the blinding requirements before the trial initiating to prevent disclosure of random assignment to the follow-up personnel in any unplanned way.
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* General inclusion criteria: 1. Age above 18 years old, no limit on the gender; 2. Angiography is considered necessary and feasible by investigator, and PCI will be performed if necessary; 3. Suspected coronary heart disease, stable angina pectoris, unstable angina pectoris, non-culprit vascular assessment in participants with acute non-ST-segment elevation myocardial infarction, and non-culprit vascular assessment in patients with previous ST-segment elevation acute myocardial infarction; 4. Participants voluntarily participate in this clinical trial and sign informed consent form. * Coronary angiography inclusion criteria: The presence of at least one stenosis and meets the following imaging findings: 1. The degree of coronary artery stenosis≥50% and ≤90% by visual measurement; 2. The reference diameter of the stenotic segment≥2.25 mm by visual measurement; 3. The investigator visually observes the target vessel through angiographic images, and consider that PCI surgery is technically feasible.
Exclusion criteria
* General
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MACE | 1 year | A composite of all-cause death, myocardial infarction (MI), and unplanned revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Death | 1 month, 6 months, 1 year, 2 years | Cardiovascular, non-cardiovascular, and undetermined death |
| MI | 1 month, 6 months, 1 year, 2 years | Target vessel related and non-target vessel related MI |
| Target vessel revascularization (TVR) | 1 month, 6 months, 1 year, 2 years | The ischemia driven and non-ischemia driven TVR |
| Any coronary artery revascularization | 1 month, 6 months, 1 year, 2 years | The ischemia driven and non-ischemia driven revascularization |
| MACE（excluding PCI-related MI） | 1 month, 1 year, 2 years | A composite of all-cause death, myocardial infarction (excluding PCI-related), and unplanned revascularization |
| Evaluation of health economics | 1 month, 6 months, 1 year | Cost-utility analysis and computation of incremental cost-effectiveness ratio. |
| Analysis of participant discomfort during the operation (none/mild/moderate/severe ) | During the operation | During the caFFR or FFR detection, the operator will ask the participant if there is discomfort (none/mild/moderate/severe ) and what kind of discomfort(such as palpitation, chest stuffy , nausea, dizziness, foreign body invasion ), and fill out a questionnaire after the operation.The discomfort of all participants caused by the use of drugs, intervention, etc. during the caFFR or FFR detection will be analyzed. |
| The changes of PCI strategy depending on caFFR/FFR information | During the operation | Before randomization,the operators will be asked to provide their planned treatment strategy based on the angiographic information alone. After randomization and functional assessment,we will record how caFFR/FFR changed the treatment strategy. |
| Definite or probable stent thrombosis | 1 month, 6 months, 1 year, 2 years | Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase |
Countries
China
Contacts
Primary ContactYanjun Gong, MD
Outcome results
None listed